Drug Profile
Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics
Alternative Names: Fleximer®-ADC - Adimab/Mersana Therapeutics; Trastuzumab-m-Dolaflexin®; Trastuzumab-s-Dolaflexin®Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Adimab; Mersana Therapeutics
- Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
- 30 Oct 2017 Mersana Therapeutics plans a phase I trial for XMT 1536 in Cancer in early 2018 (CTP#279524)